By Deena Beasley (Reuters) -CVS Health, which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' ...

The deal gives Gilead ownership of a technology that can genetically modify immune cells inside the body, an approach could ...

Gilead Sciences' unit Kite Pharma said on Thursday it will acquire privately-held biotech firm Interius BioTherapeutics for ...

The owner of the United States' largest pharmacy benefit manager (PBM) is declining to cover Gilead Sciences’ long-acting HIV ...

The Gilead HIV prevention shot , called Yevtugo, is highly effective, but its list price is $28, 218 a year in the U.S.

Market Catalysts Host Julie Hyman recaps some of the trending tickers on Thursday, Aug. 21, including Coty (COTY), Gilead ...

Gilead Sciences is accelerating its growth rate and Yeztugo might be another major blockbuster. GILD stock is still trading ...

Gilead has become the latest pharma to strengthen its in-vivo cell therapy credentials this year, paying $350 million for CAR-T developer Interius BioTherapeutics. | Gilead has become the latest ...

Gilead Sciences agreed to buy Interius BioTherapeutics, a privately held biotechnology company developing in-vivo CAR therapeutics, for $350 million. Gilead on Thursday said the deal complements the ...

CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing nearly $290 million in Medicare overcharge penalties.

Gilead Sciences Inc. Chief Executive Officer Daniel O’Day said the company’s new HIV prevention drug Yeztugo should be able ...

Gilead Sciences on Thursday reported flat second-quarter earnings on slightly higher revenue and raised its full-year ...